Merus N.V. announced that Dr. Ton Logtenberg will step down as CEO, President, Principal Financial Officer and Director of the Company on December 31, 2019. The Merus board of directors has nominated Dr. Sven (Bill) Ante Lundberg, currently a non-executive director on the Merus board, to succeed Dr. Logtenberg as CEO, President and Principal Financial Officer of the company. In accordance with Dutch law, the appointment will be voted on during an extraordinary general meeting of shareholders on December 31, 2019.

Dr. Logtenberg will remain on as a senior advisor for Merus during the transition over the next year. Dr. Bill Lundberg joined Merus' Board of Directors in June 2019, and he brings more than 15 years of experience managing and leading biotechnology research and development along with a background as a medical oncologist. He has extensive experience across all aspects and phases of drug development in both academic and industry settings.

Most recently, Dr. Lundberg served as Chief Scientific Officer at CRISPR Therapeutics and as Head of Translational Medicine at Alexion Pharmaceuticals.